Lowering the Rate of Episodes
Nativa offers a new drug for baseline therapy of asthma. It is the only Russian combination for treatment of asthma. Its core components budesonide and formoterol have different mechanisms of action, but in combination they provide additive effect, improving the lung function and decreasing the frequency of asthma episodes. The combination of inhaled budesonide (200 µg/day) and formoterol (18 µg/day) increases their therapeutic effectiveness and provides anti-inflammatory effects versus monotherapy with budesonide at 800 µg/od.
Patients with asthma and chronic obstructive pulmonary disease (COPD) using a fixed combination of budesonide and formoterol have less asthma episodes versus other combined and monodrugs.
The drug can be used for maintenance therapy and for acute asthma episodes.
Russian market size of the international non-proprietary name in the form of dosed powder for inhalations in 2015 was about 2 mln packages. Nativa is planning to bring to market about 500 thos packages in H2 2016.
The drug is included in the current list of essential and vital drugs for 2016.